Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study

Journal of Nuclear Medicine

Volumn 50, Issue 5, 2009, Pages 732-737

  Fast, Søren ^a   Nielsen, Viveque Egsgaard ^a   Grupe, Peter ^a   Bonnema, Steen Joop ^a   Hegedüs, Laszlo ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Endocrinology; Goiter; Radioiodine therapy; Radionuclide therapy; Radiotracer tissue kinetics; Recombinant thyrotropin; RhTSH

Indexed keywords

CALCITONIN; IODINE 131; LIOTHYRONINE; PLACEBO; RADIOISOTOPE; RECOMBINANT THYROTROPIN; THYROTROPIN; THYROXINE; RADIOACTIVE IODINE; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE SEQUENCE; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; HUMAN; IODINE 131 UPTAKE TEST; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL; THYROID FUNCTION TEST; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; EVIDENCE BASED MEDICINE; GENETICS; GOITER; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EVIDENCE-BASED MEDICINE; FEMALE; GOITER; HUMANS; IODINE RADIOISOTOPES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SINGLE-BLIND METHOD; THYROTROPIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 66149103709     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.060152     Document Type: Article

References (30)

1. Bonnema SJ, Bennedbaek FN, Wiersinga WM, Hegedus L. Management of the nontoxic multinodular goitre: a European questionnaire study. Clin Endocrinol (Oxf). 2000;53:5-12.
2. Bonnema SJ, Bennedbaek FN, Ladenson PW, Hegedus L. Management of the nontoxic multinodular goiter: a North American survey. J Clin Endocrinol Metab. 2002;87:112-117.
3. Sdano MT, Falciglia M, Welge JA, Steward DL. Efficacy of thyroid hormone suppression for benign thyroid nodules: meta-analysis of randomized trials. Otolaryngol Head Neck Surg. 2005;133:391-396.
4. Fast S, Bonnema SJ, Hegedus L. The majority of Danish nontoxic goitre patients are ineligible for levothyroxine suppressive therapy. Clin Endocrinol (Oxf). 2008;69:653-658.
5. AACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2006;12:63-102.
6. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142.
7. 123I thyroid uptake and thyroid size at 24, 48, and 72 hours after the administration of recombinant human thyroid-stimulating hormone to normal volunteers. J Clin Endocrinol Metab. 2006;91:506-510.
8. Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab. 2001;86:1660-1664.
9. Albino CC, Mesa CO Jr, Olandoski M, et al. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab. 2005;90:2775-2780. (Pubitemid 40686323)
10. Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab. 2000;85:3592-3596.
11. Nieuwlaat WA, Huysmans DA, van den Bosch HC, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab. 2003;88:3121-3129.
12. Paz-Filho GJ, Mesa-Junior CO, Olandoski M, et al. Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone. Braz J Med Biol Res. 2007;40:1661-1670.
13. Silva MN, Rubio IG, Romao R, et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf). 2004;60:300-308. (Pubitemid 38297119)
14. Bonnema SJ, Nielsen VE, Boel-Jorgensen H, et al. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab. 2007;92:3424-3428.
15. Nielsen VE, Bonnema SJ, Boel-Jorgensen H, Grupe P, Hegedus L. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med. 2006;166:1476-1482.
16. Bonnema SJ, Nielsen VE, Boel-Jorgensen H, et al. Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration. J Clin Endocrinol Metab. 2008;93:3981-3984.
17. Nielsen VE, Bonnema SJ, Hegedus L. Effects of 0.9 mg recombinant human thyrotropin on thyroid size and function in normal subjects: a randomized, double-blind, cross-over trial. J Clin Endocrinol Metab. 2004;89:2242-2247.
18. Nielsen VE, Bonnema SJ, Hegedus L. Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial. J Clin Endocrinol Metab. 2006;91:1317-1322.
19. Bonnema SJ, Andersen PB, Knudsen DU, Hegedus L. MR imaging of large multinodular goiters: observer agreement on volume versus observer disagreement on dimensions of the involved trachea. AJR. 2002;179:259-266.
20. Hegedus L, Perrild H, Poulsen LR, et al. The determination of thyroid volume by ultrasound and its relationship to body weight, age, and sex in normal subjects. J Clin Endocrinol Metab. 1983;56:260-263.
21. 123I uptake in iodide treated normal subjects. J Clin Endocrinol Metab. 2001;86:437-440.
22. Cohen O, Ilany J, Hoffman C, et al. Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur J Endocrinol. 2006;154:243-252.
23. Braverman L, Kloos RT, Law B Jr, Kipnes M, Dionne M, Magner J. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract. 2008;14:832-839.
24. Paz-Filho GJ, Mesa CO, Carvalho GA, Goedert CA, Graf H. Recombinant human TSH associated with radioiodine does not have further effects on thyroid volume and function after 2 years. Clin Endocrinol (Oxf). 2008;69:345-346.
25. Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, Corstens FH, Huysmans DA. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab. 2001;86:5330-5336.
26. Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab. 1999;84:3636-3641.
27. Le Moli R, Wesche MF, Tiel-Van Buul MM, Wiersinga WM. Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre. Clin Endocrinol (Oxf). 1999;50:783-789.
28. 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial. J Clin Endocrinol Metab. 2005;90:79-83.
29. 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab. 2004;89:4439-4444.
30. Pedersen-Bjergaard U, Kirkegaard C. Serum TSH and the response to radioiodine treatment of toxic multinodular goitre. Eur J Endocrinol. 1997;137:365-369.